$ cat ./records/funded-the-development-of-menafrivac-a-50-cent-meningitis-vaccine-2010.txt
Funded the development of MenAfriVac — a 50-cent meningitis vaccine for Africa
[RECORD.TXT] · cat --full
Gates Foundation funding helped develop and deploy MenAfriVac, a meningitis A vaccine priced at under $0.50 per dose specifically for the 'meningitis belt' across sub-Saharan Africa. Previous meningitis vaccines cost ten times as much and had not reached the region at scale. Within three years of the vaccine's introduction, meningitis A cases in the affected region fell by over 99%, eliminating epidemic waves that had devastated the region for over a century.
Source: https://www.gatesfoundation.org/ideas/articles/meningitis-africa
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Launched GatesNotes — one of the world's most widely read personal platforms
Next →
Co-founded the Giving Pledge — a global commitment of billionaire wealth
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.